EGFR and non-small cell lung carcinoma: At present, given that the efficacy of combining PD-1/PD-L1 inhibitors with EGFR TKIs as an option for EGFR-mutant advanced NSCLC patients is still not very clear, and serious adverse reactions seem inevitable, clinicians need to weight the advantages and corresponding disadvantages when making decisions.